Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulation and the heart.

R C Becker1

  • 1Anticoagulation Services, University of Massachusetts Medical School, Worcester, MA 01655, USA.

Journal of Thrombosis and Thrombolysis
|November 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.

Journal of thrombosis and thrombolysis·2014
Same author

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.

Journal of clinical pharmacology·2014
Same author

A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Antidote control of aptamer therapeutics: the road to a safer class of drug agents.

Current pharmaceutical biotechnology·2012
Same author

Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.

Journal of thrombosis and thrombolysis·2011
Same author

The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).

Thrombosis and haemostasis·2011
Same journal

Multi target effects of Allium macrostemon against myocardial infarction: an integrated network pharmacology, molecular docking, and experimental study.

Journal of thrombosis and thrombolysis·2026
Same journal

Comparative effectiveness of figure-of-eight suture and manual compression for femoral venous hemostasis after atrial fibrillation ablation: A grade assessed meta-analysis.

Journal of thrombosis and thrombolysis·2026
Same journal

Tissue factor-related biomarkers during combined androgen blockade in patients with prostate cancer: A brief report.

Journal of thrombosis and thrombolysis·2026
Same journal

Opioid use disorder and clinical outcomes following percutaneous coronary intervention for acute coronary syndromes.

Journal of thrombosis and thrombolysis·2026
Same journal

Sex-based differences in clinical outcomes among cardiogenic shock patients treated with mechanical circulatory support.

Journal of thrombosis and thrombolysis·2026
Same journal

IGF-1 axis: The signalling bond in cancer-associated thrombosis and cachexia?

Journal of thrombosis and thrombolysis·2026
See all related articles

Cardiovascular disease increases thrombosis risk, leading to heart attack and stroke. Anticoagulant therapy is crucial for preventing and treating these thrombotic disorders in the cardiovascular system.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Cardiovascular diseases elevate thrombosis risk, potentially causing myocardial infarction, cardiac death, and stroke.
  • Valvular heart disease and prosthetic materials disrupt blood flow, promoting platelet aggregation and coagulation.
  • Understanding thrombosis pathophysiology is key to preventing cardiovascular events.

Purpose of the Study:

  • To review the role of anticoagulant therapy in managing cardiovascular thrombotic disorders.
  • To highlight the importance of clinical trials in establishing effective antithrombotic strategies.

Main Methods:

  • Literature review focusing on thrombosis mechanisms in cardiovascular disease.
  • Analysis of the role of anticoagulant therapy in clinical settings.

Related Experiment Videos

  • Discussion of principles guiding antithrombotic treatment development.

    • Main Results:

    • Anticoagulant therapy is a cornerstone in preventing and treating cardiovascular thrombosis.
    • Physiologic and pathobiologic factors influence thrombosis development and management.
    • Clinical trials are essential for validating new antithrombotic treatments.

    Conclusions:

    • Anticoagulant therapy plays a vital role in managing thrombotic risks associated with cardiovascular disease.
    • Further research through clinical trials is needed to optimize antithrombotic treatments for broad application.